Impact Therapeutics Nets HK$759.5 Million From Hong Kong IPO Ahead of Debut

MT Newswires Live05-13

Impact Therapeutics (HKG:7630) raised HK$759.5 million in net proceeds from its initial public offering in Hong Kong.

The final offer price was set at HK$20.10 per H-share, near the lower end of the offer price range, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.

The Chinese biotech company offered nearly 42 million H-shares in the global offering.

The Hong Kong public offer was 2,282.4 times subscribed, with a final allocation of 4.2 million shares, representing 10% of the total offering.

The international offering was 24.58 times subscribed, with a final allocation of 37.8 million shares, or 90% of the total offering.

An over-allocation of 6.3 million shares was made under the global offering.

Cornerstone investors, including Nanjing Biotech and Pharmaceutical Valley Construction and Development, Huang River Investment, and LAV Star, were allocated about 13.9 million shares representing 33.19% of the global offering, according to the filing.

Impact Therapeutics is scheduled to debut on the Hong Kong bourse on Wednesday, May 13.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635257392?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 06:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635257392","market":"us","top_or_hot":-1,"title":"Impact Therapeutics Nets HK$759.5 Million From Hong Kong IPO Ahead of Debut","media":"MT Newswires Live","content":"<html><body><p> Impact <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:7630) raised HK$759.5 million in net proceeds from its initial public offering in Hong Kong.</p><p>The final offer price was set at HK$20.10 per H-share, near the lower end of the offer price range, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.</p><p>The Chinese biotech company offered nearly 42 million H-shares in the global offering.</p><p>The Hong Kong public offer was 2,282.4 times subscribed, with a final allocation of 4.2 million shares, representing 10% of the total offering.</p><p>The international offering was 24.58 times subscribed, with a final allocation of 37.8 million shares, or 90% of the total offering.</p><p>An over-allocation of 6.3 million shares was made under the global offering.</p><p>Cornerstone investors, including Nanjing Biotech and Pharmaceutical Valley Construction and Development, Huang River Investment, and LAV <a href=\"https://laohu8.com/S/SGU\">Star</a>, were allocated about 13.9 million shares representing 33.19% of the global offering, according to the filing.</p><p>Impact Therapeutics is scheduled to debut on the Hong Kong bourse on Wednesday, May 13.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Impact Therapeutics Nets HK$759.5 Million From Hong Kong IPO Ahead of Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImpact Therapeutics Nets HK$759.5 Million From Hong Kong IPO Ahead of Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-13 06:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Impact <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:7630) raised HK$759.5 million in net proceeds from its initial public offering in Hong Kong.</p><p>The final offer price was set at HK$20.10 per H-share, near the lower end of the offer price range, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.</p><p>The Chinese biotech company offered nearly 42 million H-shares in the global offering.</p><p>The Hong Kong public offer was 2,282.4 times subscribed, with a final allocation of 4.2 million shares, representing 10% of the total offering.</p><p>The international offering was 24.58 times subscribed, with a final allocation of 37.8 million shares, or 90% of the total offering.</p><p>An over-allocation of 6.3 million shares was made under the global offering.</p><p>Cornerstone investors, including Nanjing Biotech and Pharmaceutical Valley Construction and Development, Huang River Investment, and LAV <a href=\"https://laohu8.com/S/SGU\">Star</a>, were allocated about 13.9 million shares representing 33.19% of the global offering, according to the filing.</p><p>Impact Therapeutics is scheduled to debut on the Hong Kong bourse on Wednesday, May 13.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635257392","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635257392","pubTimestamp":1778623413,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Impact Therapeutics (HKG:7630) raised HK$759.5 million in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$20.10 per H-share, near the lower end of the of","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","07630":"英派药业-B","SPCX":"SPAC and New Issue ETF","BK4007":"制药","IPOS":"Renaissance International IPO ETF","BK4539":"次新股"},"translate_title":"Impact Therapeutics在香港IPO上市前净赚7.595亿港元","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1.5,"LENZ":1.5,"07630":1,"SPCX":1.5},"content_text":"Impact Therapeutics (HKG:7630) raised HK$759.5 million in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$20.10 per H-share, near the lower end of the offer price range, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.The Chinese biotech company offered nearly 42 million H-shares in the global offering.The Hong Kong public offer was 2,282.4 times subscribed, with a final allocation of 4.2 million shares, representing 10% of the total offering.The international offering was 24.58 times subscribed, with a final allocation of 37.8 million shares, or 90% of the total offering.An over-allocation of 6.3 million shares was made under the global offering.Cornerstone investors, including Nanjing Biotech and Pharmaceutical Valley Construction and Development, Huang River Investment, and LAV Star, were allocated about 13.9 million shares representing 33.19% of the global offering, according to the filing.Impact Therapeutics is scheduled to debut on the Hong Kong bourse on Wednesday, May 13.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635257392","isCrawlerRequest":true}